In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cypress Bioscience, Inc.

http://www.cypressbio.com

Latest From Cypress Bioscience, Inc.

Digital Health Roundup: What’s Hot On Investment; Diabetes; AI

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb looks back at ADA 2023 highlights and her interviews with diabetes company execs. Reed Miller discusses his Cardio Conversation with Volta Medical and Hannah Daniel discusses the FDA’s Clinical Decision Support Software final guidance.

Artificial Intelligence Business Strategies

Cardio Conversations: 'Trials, Trials, Trials!' Volta Has Big Ambitions For AI In EP

In this edition of Cardio Conversations, Medtech Insight editor Reed Miller talked to Théophile Mohr Durdez, the CEO and co-founder of Volta Medical, a Marseille-based company applying artificial intelligence to electrophysiology. Volta has raised over €70m and is sponsoring the TAILORED AF trial to show that its software can make atrial fibrillation ablation more effective.

Cardio Conversations Clinical Trials

Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence

The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.

Scrip Asks Artificial Intelligence

Finance Watch: Prime Medicine Launches Second-Largest IPO In Second Half Of 2022

Public Company Edition: Prime Medicine raised $175m, making its offering the sixth-largest out of 19 biopharma IPOs in the US this year. Also, Oculis and AUM opted to go public via SPAC mergers, Insmed raised $775m from multiple financings and Dice capitalized on positive data with a $300m offering.

Financing Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Services
  • In Vitro Diagnostics
    • Therapeutic Drug Monitoring
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • Other Names / Subsidiaries
    • Cellatope Corporation
    • Proprius Pharmaceuticals, Inc., Ramius LLC
    • Royalty Pharma
UsernamePublicRestriction

Register